Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Conditions
Brief summary
This phase II trial studies how well abatacept, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that is resistant to chemotherapy. Abatacept may block certain proteins that are present on multiple myeloma cells that have been shown to protect against chemotherapy. Drugs used in chemotherapy, such as ixazomib citrate and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abatacept, ixazomib citrate, and dexamethasone may work better at treating patients with multiple myeloma resistant to chemotherapy.
Detailed description
PRIMARY OBJECTIVES: I. To determine the therapeutic efficacy (as measured by response rate) of abatacept + ixazomib citrate (ixazomib) + dexamethasone in multiple myeloma patients who have relapsed (or who are primary refractory) following treatment with their first proteasome inhibitor-containing regimen (excluding ixazomib), compared to historical controls of ixazomib + dexamethasone. SECONDARY OBJECTIVES: I. To assess the toxicity profile of abatacept + ixazomib + dexamethasone in multiple myeloma patients who have relapsed (or who are primary refractory) following treatment with their first proteasome inhibitor-containing regimen, compared to historical controls of ixazomib + dexamethasone. II. To assess progression-free and overall survival profile of abatacept + ixazomib + dexamethasone in multiple myeloma patients who have relapsed (or who are primary refractory) following treatment with their proteasome inhibitor-containing regimen, compared to historical controls of ixazomib + dexamethasone. TERTIARY OBJECTIVES: I. Assess whether myeloma expression of CD28, CD86, serum kynurenine and/or IL-6 are correlated with specific clinical outcomes. OUTLINE: Patients receive abatacept intravenously (IV) over 30 minutes on day 1 of course 1, then subcutaneously (SC) on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate orally (PO) once daily (QD) on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 3 months thereafter.
Interventions
BIOLOGICALAbatacept
Given IV and SC
DRUGDexamethasone
Given PO
DRUGIxazomib Citrate
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
Bristol-Myers Squibb
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with multiple myeloma who have relapsed (or who are primary refractory) following treatment with a proteasome inhibitor-containing regimen (excluding ixazomib) and who have not been treated with a second proteasome inhibitor (ixazomib, bortezomib, carfilzomib or other proteasome inhibitor). * Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 at study entry * Must be free of systemic infection: * Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection * Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment * Absolute neutrophil count \>= 750/mm\^3 * Platelet count \>= 25,000/mm\^3 * Creatinine clearance \>= 30 mL/min * Total bilirubin =\< 3 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x ULN * Patient's multiple myeloma cells are positive for CD28 or CD86 expression by flow cytometry or immunohistochemistry (in any proportion) CD28 or CD86 positivity can have been determined on previous bone marrow aspirates or biopsies * Disease free of prior malignancies for \> 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma ?in situ? of the cervix or breast * Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Prior treatment with ixazomib * Inability to take ixazomib or abatacept * Life expectancy less than 4 months * Patients with a known diagnosis of plasma cell leukemia * Known active tuberculosis or fungal infection * Known seropositive for or active viral infection with, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or, which confounds the ability to interpret data from the study * Pregnant or nursing female participants * Unwilling or unable to follow protocol requirements * Any condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive study drug * Received an investigational agent within 30 days prior to enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients | 1 cycle of 28 days | Will be compared to historical controls of ixazomib citrate + dexamethasone. Responses to treatment will be measured by serum immunoglobulins, serum free kappa and lambda light chains, serum protein electrophoresis/immunofixation electrophoresis, and 24-hour urine protein electrophoresis/immunofixation. International uniform response criteria will be used. The anti-myeloma activity will be evaluated on an exploratory basis and will be summarized using descriptive statistics or graphical methods. No formal comparison will be carried forth. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | Up to 30 days after last dose | The adverse events and drug related toxicities will be summarized by grade using frequencies and relative frequencies. The rate of grade 3 or higher toxicities that are probably or definitely related to abatacept will be reported with 90% confidence intervals obtained using Jeffrey?s prior method. |
| Overall Survival | From the date of the first study treatment until initiation of a new therapy, death, or end of follow-up (up to 5 years); whichever occurs first. | Defined as the time from treatment initiation until death or last follow-up. Will be summarized using standard Kaplan-Meier methods; where estimates of median survival and survival rates will be obtained with 90% confidence intervals. |
| Progression-free Survival | From the date of the first study treatment to the date of first observed disease progression or death due to any cause, assessed up to 5 years | Defined as the time from treatment initiation until disease progression, death, or last follow-up. Will be summarized using standard Kaplan-Meier methods; where estimates of median survival and survival rates will be obtained with 90% confidence intervals. |
Other
| Measure | Time frame | Description |
|---|---|---|
| CD28 and CD86 Expression Assessed by Flow Cytometry | Up to 5 years | The expression/levels and response will be evaluated using logistic regression models. |
| Serum Kynurenine and IL-6 Levels | Up to 5 years | The association between CD28, CD86, serum kynurenine and IL-6 expression/levels and response will be evaluated using logistic regression models. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Abatacept: Given IV and SC
Dexamethasone: Given PO
Ixazomib Citrate: Given PO
Laboratory Biomarker Analysis: Correlative studies | 15 |
| Total | 15 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 1 |
Baseline characteristics
| Characteristic | Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) |
|---|---|
| Age, Continuous | 64.2 years STANDARD_DEVIATION 10.2 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 15 Participants |
| Region of Enrollment United States | 15 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 15 |
| other Total, other adverse events | 14 / 15 |
| serious Total, serious adverse events | 1 / 15 |
Outcome results
Primary
Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients
Will be compared to historical controls of ixazomib citrate + dexamethasone. Responses to treatment will be measured by serum immunoglobulins, serum free kappa and lambda light chains, serum protein electrophoresis/immunofixation electrophoresis, and 24-hour urine protein electrophoresis/immunofixation. International uniform response criteria will be used. The anti-myeloma activity will be evaluated on an exploratory basis and will be summarized using descriptive statistics or graphical methods. No formal comparison will be carried forth.
Time frame: 1 cycle of 28 days
Population: 1 patient experienced death prior to disease response assessment.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients | Complete Response | 1 Participants |
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients | Partial Response | 4 Participants |
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients | Stable Disease | 8 Participants |
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients | Progressive Disease | 1 Participants |
Secondary
Incidence of Adverse Events Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
The adverse events and drug related toxicities will be summarized by grade using frequencies and relative frequencies. The rate of grade 3 or higher toxicities that are probably or definitely related to abatacept will be reported with 90% confidence intervals obtained using Jeffrey?s prior method.
Time frame: Up to 30 days after last dose
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Incidence of Adverse Events Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | 5 Participants |
90% CI: [0.17, 0.54]
Secondary
Overall Survival
Defined as the time from treatment initiation until death or last follow-up. Will be summarized using standard Kaplan-Meier methods; where estimates of median survival and survival rates will be obtained with 90% confidence intervals.
Time frame: From the date of the first study treatment until initiation of a new therapy, death, or end of follow-up (up to 5 years); whichever occurs first.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Overall Survival | 33.6 months |
Secondary
Progression-free Survival
Defined as the time from treatment initiation until disease progression, death, or last follow-up. Will be summarized using standard Kaplan-Meier methods; where estimates of median survival and survival rates will be obtained with 90% confidence intervals.
Time frame: From the date of the first study treatment to the date of first observed disease progression or death due to any cause, assessed up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Abatacept, Ixazomib Citrate, Dexamethasone) | Progression-free Survival | 11.1 months |
Other Pre-specified
CD28 and CD86 Expression Assessed by Flow Cytometry
The expression/levels and response will be evaluated using logistic regression models.
Time frame: Up to 5 years
Population: These measurements were not collected and are not available for reporting.
Other Pre-specified
Serum Kynurenine and IL-6 Levels
The association between CD28, CD86, serum kynurenine and IL-6 expression/levels and response will be evaluated using logistic regression models.
Time frame: Up to 5 years
Population: These measurements were not collected and are not available for reporting.